• Corpus ID: 21064838

A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.

@article{Audinot1998ACI,
  title={A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.},
  author={Valérie Audinot and Adrian Newman-Tancredi and Alain P. Gobert and Jean Michel Rivet and Mauricette Brocco and Françoise Lejeune and Larry Gluck and I Desposte and Karin J. W. Bervoets and Anne Dekeyne and Mark J Millan},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1998},
  volume={287 1},
  pages={
          187-97
        }
}
The benzofurane (+)-S 14297, the benzamide nafadotride, the aminoindane U 99194 and the arylpiperazine GR 103,691 have been proposed as "selective" antagonists at dopamine D3 vs. D2 receptors. Herein, we compared their in vitro affinities and in vivo actions to those of the aminotetralin D3 antagonists (+)-AJ 76 and (+)-UH 232. Affinities at recombinant, human (h)D3 and/or hD2 sites were determined by employing the mixed D2/D3 antagonist [125I]-iodosulpride and the preferential D3 ligands [3H… 

Figures and Tables from this paper

Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
TLDR
The effect of SB-277011-A on isolation-induced prepulse inhibition deficit suggests that blockade of dopamine D(3) receptors may benefit the treatment of schizophrenia.
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
TLDR
S33084 is a novel, potent, selective, and competitive antagonist at hD(3)-receptors that tonically inhibit ascending dopaminergic pathways, although the latter may contribute to phasic suppression of DA release in frontal cortex.
S 33084 , a Novel , Potent , Selective , and Competitive Antagonist at Dopamine D 3-Receptors : I . Receptorial , Electrophysiological and Neurochemical Profile Compared with GR 218 , 231 and L 741 , 626
TLDR
Dopamine (DA) D3-receptors are closely related to their D2 counterparts in their primary structure, coupling to intracellular transduction mechanisms, and recognition patterns for chemically diverse ligands, although the latter may contribute to phasic suppression of DA release in frontal cortex.
S 33084 , a Novel , Potent , Selective , and Competitive Antagonist at Dopamine D 3-Receptors : II . Functional and Behavioral Profile Compared with GR 218 , 231 and L 741 , 626
TLDR
A novel benzopyranopyrrole, S33084, that behaves as a potent, competitive, and selective (.100-fold) antagonist at cloned, human and native rat D3versus hD2-receptors (Table 1), and which shows only negligible lower affinity for all other sites examined to date.
[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors
TLDR
[3H]S33084 is a highly potent and selective radioligand at dopamine D3 receptors, which should be of considerable use for their characterisation.
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.
TLDR
D(2)-receptors are principally involved in these paradigms, although D(3)-receptionors may contribute to induction of hypothermia and PEs, and S33084 was inactive in models of potential antipsychotic and extrapyramidal activity and failed to modify spontaneous locomotor behavior.
...
...

References

SHOWING 1-10 OF 108 REFERENCES
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
TLDR
Data demonstrate that the novel naphthofurane, (+)-S 14297, is a selective ligand (antagonist) at dopamine D3 receptors and suggest that their activation mediates hypothermia in the rat.
S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats.
Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells.
The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats.
The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (+)-PD 128907, in the rat
The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonist.
Identification , characterization , and localization of the dopamine D 3 receptor in rat brain using 7-[ 3 H ] hydroxy-NN-din-propyl-2-aminotetralin ( guanine nucleotide-binding regulatory protein-coupled receptor / antipsychotics / islands of Calleja / cerebellum / nucleus accumbens )
We have identified 7-[3Hlhydroxy-N,N-di-npropyl-2-aminotetralin ([3H]7-OH-DPAT) as a selective probe for the recently cloned dopamine D3 receptor and used it to assess the presence of this receptor
[3H]quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study.
TLDR
The utility of [3H]quinpirole to label D3 as well as D2 dopamine receptors is shown, in concordance with the recently reported distribution of D3 receptor mRNA in these brain regions.
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
TLDR
The data suggest that D3 (auto)receptors control synthesis and release of DA in dopaminergic pathways innervating the limbic system, cortex and striatum and that D2/D3 receptor antagonist haloperidol modified DA turnover upon administration alone.
...
...